Showing results (1341-1350 of 1,557) with videos related to
Sort By:
Pageof 156
Cell|November 24, 2014
CDK7 inhibition suppresses super-enhancer-linked oncogenic transcription in MYCN-driven cancerEdmond Chipumuro, Eugenio Marco, Camilla L Christensen, et al.Science Advances|August 25, 2017
Vomocytosis of live pathogens from macrophages is regulated by the atypical MAP kinase ERK5Andrew S Gilbert, Paula I Seoane, Poppy Sephton-Clark, et al.Journal of Medicinal Chemistry|July 31, 2014
Discovery of type II inhibitors of TGFβ-activated kinase 1 (TAK1) and mitogen-activated protein kinase kinase kinase kinase 2 (MAP4K2)Li Tan, Tyzoon Nomanbhoy, Deepak Gurbani, et al.Nature Chemical Biology|December 19, 2017
Pharmacological perturbation of CDK9 using selective CDK9 inhibition or degradationCalla M Olson, Baishan Jiang, Michael A Erb, et al.Molecular and Cellular Biology|June 14, 2021
The Cyclin-Dependent Kinase 8 (CDK8) Inhibitor DCA Promotes a Tolerogenic Chemical Immunophenotype in CD4+ T Cells via a Novel CDK8-GATA3-FOXP3 PathwayAzlann Arnett, Keagan G Moo, Kaitlin J Flynn, et al.Nature Communications|January 31, 2017
THZ1 targeting CDK7 suppresses STAT transcriptional activity and sensitizes T-cell lymphomas to BCL2 inhibitorsFlorencia Cayrol, Pannee Praditsuktavorn, Tharu M Fernando, et al.BMJ Open Respiratory Research|February 27, 2023
International perspective on research priorities and outcome measures of importance in the care of children with acute exacerbations of asthma: a qualitative interview studyCharmaine S Gray, Yao Xu, Franz E Babl, et al.Elife|November 16, 2018
Targeted degradation of BRD9 reverses oncogenic gene expression in synovial sarcomaGerard L Brien, David Remillard, Junwei Shi, et al.Science Translational Medicine|November 20, 2024
Disrupting the RNA polymerase II transcription cycle through CDK7 inhibition ameliorates inflammatory arthritisXi Chen, Gayathri Shibu, Baila A Sokolsky, et al.Cancer Research Communications|December 5, 2022
Inhibiting ERK5 overcomes breast cancer resistance to anti-HER2 therapy by targeting the G1/S cell cycle transitionJingwei Zhang, Adam J Pearson, Nitin Sabherwal, et al.Pageof 156